St John’s Wort in the treatment against Major Depression Disorder

Year 2015, Volume: 1 Issue: 2, 16 - 21, 30.01.2016

Sajad Bhat

Abstract

Depression is a complex mood disorder with many types and treated in a number of ways. There are large numbers of synthetic drugs which are used in treating major depressive disorder. However they are also found to have bad impact on the health of a patient. Depression is multifactorial phenomenon, in which hormonal and neurotransmitter imbalance plays imperative role in its causation. Though large number of pharmaceutical drugs is available but they also pose serious threat due to extended use as serious side effects also develop. It is very important to look for antidepressants from natural sources which are advantageous, less hazardous and has least side effects on human health. This article aims to focus on specific natural antidepressant St John’s Wort and how it can act as alternative medicine exhibiting the potential for the treatment of depression.

Keywords

Depression, Natural Antidepressants, St John Worts

References

• Kruijshaar ME, Barendregt J, Vos T, et al. Life time prevalence estimates of major depression: an indirect estimation method and quantification of recall bias. Eur J Epidemiol. 2005; 20:103-111. [DOI via Crossref] [Pubmed]
• Smith AJ, Sketris I, Cooke C, et al. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf. 2008; 17:697-706. [DOI via Crossref] [Pubmed]
• Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment. 45th ed. SanFrancisco, CA: McGrawHill; 2006:1065-1066.
• Mann JJ. The medical management of depression. N Engl J Med. 2005; 353:1819-1834. [DOI via Crossref] [Pubmed]
• Bhat SA, Wani AL, Ara A, Saidullah B. An epidemiological study on depression and its comorbidity. Int J of Latest Res Science and Tech. 2014; 3(4): 12-17.
• Wani AL, Ara A, Bhat SA. "Blood Injury and Injection Phobia: The Neglected One," Behav Neurol 2014; vol. Article ID 471340, 7 pages, 2014. [DOI via Crossref] [DOI via Crossref]
• Hansson L. Quality of life in depression and anxiety. Int Rev Psychiatry 2002; 14:185-189. [DOI via Crossref]
• Andrews G, Titov N. Depression is very disabling. Lancet. 2007;370:808-809. [DOI via Crossref]
• Tomas K, Coleman P. Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey. J Public Health. 2004;26:152-157. [DOI via Crossref] [Pubmed]
• Zhou SF, Lai X. An update of clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab. 2008; 9:394-409. [DOI via Crossref] [Pubmed]
• Tindle HA, Davis RB, Phillips RS, Eisenberg DM.Trends in the use of complementary and alternative medicine by US adults: 1997-2002. Altern ther Health Med. 2005; 11:42-49. [Pubmed]
• Mehta, Sweety (2012-12-18). Pharmacognosy of St john's Wort. Pharmaxchange.info. Retrieved 2014-02-16.
• Nathan, PJ. "Hypericum perforatum (St John's Wort): a nonselective reuptake inhibitor? A review of the recent advances in its pharmacology". Journal of psychopharmacology (Oxford, England). 2001;15(1):47–54. [DOI via Crossref]
• Ernst E 1999 Second thoughts about safety of St John's wort. Lancet 354; 2014-2016. [DOI via Crossref]
• Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W & Melchart D. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. Br Med J. 1996; 313 253-258. [DOI via Crossref] [Pubmed] [PMC Free Fulltext]
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug–drug interactions: an update. Curr Drug Metabl. 2002; 3:13–37. [DOI via Crossref]
• Mueller SC, Uehleke B,Woehling H, et al. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75:546–557. [DOI via Crossref] [Pubmed]
• Izzo AA. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther.2004; 42: 139–148. [DOI via Crossref]
• Muller WE, Singer A, Wonnermann M, Hafner U, Rolli M and Schafer C, Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract, Pharmacopsychiatry. 1998; Suppl (1) 16-21
• Chatterjee SS, Bhattacharya SK, Wonnermann M, Singer A and Muller WE, Hyperforin as a possible antidepressant component of Hypericum extract, Life Sci. 1998; 63: 499-510. [DOI via Crossref]
• Barnes J, Anderson LA and Phillipson JD, St. John's wort (H. perforatum L): a review of its chemistry, pharmacology and clinical properties, J Pharm Pharmacol. 2001:53: 583-600. [DOI via Crossref] [Pubmed]
• Singer A, Wonnermann M and Muller WE, Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+, J Pharmacol Exp Ther. 1999: 290: 1363-1368. [Pubmed]
• Calapai G, Crupi A, Firenzuoli F, Inferrera G, Squadrito F, Parisi A, De Sarro G and CaputiA, Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry, 2001; 34(2): 45-49. [DOI via Crossref] [Pubmed]
• Yu PH, Effect of the Hypericum perforatum on serotonin turnover in the mouse brain, Pharmacopsychiatry. 2000; 33(2): 60-65. [DOI via Crossref] [Pubmed]
• Muller WE, Rolli M, Schafer C and Hafner U, Effects of Hypericum extract in biochemical models of antidepressant activity, Pharmacopsychiatry. 1997; 30(2):102-107. [DOI via Crossref] [Pubmed]
• Muller WE, Singer A and Wonnemann M, Mechanism of action of St. John's wort extract, Schweiz Rundsch Med Prax. 2000; 89(50): 2111-2121.
• Sarris J. St. John's Wort for the treatment of psychiatric disorders. Psychiatr Clin North Am. 2013; 36(1):65-72. [DOI via Crossref] [Pubmed]
• Pirotta M, Willis K, Carter M, Forsdike K, Newton D, Gunn J. 'Less like a drug than a drug': The use of St John's Wort among people who self-identify as having depressionand/or anxiety symptoms. Complement Ther Med. 2014; 22(5):870-6. [DOI via Crossref] [Pubmed]
• Sell TS, Belkacemi T, Flockerzi V, Beck A. Protonophore properties of hyperforin are essential for its pharmacological activity. Sci Rep. 2014;4:7500. [DOI via Crossref] [Pubmed] [PMC Free Fulltext]
• Tian J, Zhang F, Cheng J, Guo S, Liu P, Wang H. Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L. Sci Rep. 2014; 4:5632. [DOI via Crossref] [Pubmed] [PMC Free Fulltext]
• Vance KM, Ribnicky DM, Hermann GE, Rogers RC. St. John's Wort enhances the synaptic activity of the nucleus of the solitary tract. Nutrition. 2014; 30(7-8 Suppl): S37-42.
• Bukhari IA, Dar A.Behavioral profile of ypericum perforatum (St. John's Wort) extract. A comparison with standard anti depressants in animal models of depression. Eur Rev Med Pharmacol Sci. 2013; 17(8):1082-1089. [Pubmed]
• Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000448. [DOI via Crossref]
• Bouron A, Lorrain E. Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature. Encephale. 2014; 40(2):108-13. [DOI via Crossref] [Pubmed]
• Husain GM, Chatterjee SS, Singh PN, Kumar V. Beneficial effect of Hypericum perforatum on depression and anxiety in a type 2 diabetic rat model. Acta Pol Pharm. 2011;68(6):913-8. [Pubmed]
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352 (11): 1112–20. [DOI via Crossref] [Pubmed]
• Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry.2011; 59 (11): 1046–51. [DOI via Crossref] [Pubmed]
• Isbister GK, Buckley NA, Whyte IM."Serotonin toxicity: a practical approach to diagnosis and treatment". Med J Aust. 2007; 187 (6): 361-5. [Pubmed]
• Strawn JR, Keck PE, Caroff SN. "Neuroleptic malignant syndrome". Am J Psychiatry. 2007; 164 (6): 870–6. [DOI via Crossref] [Pubmed]